Timed sequential chemotherapy for advanced acute myeloid leukemia

被引:13
作者
Archimbaud, E
Leblond, V
Fenaux, P
Dombret, H
Cordonnier, C
Dreyfus, F
ConyMakhoul, P
Tilly, H
Troussard, X
Auzanneau, G
Thomas, X
Ffrench, M
Marie, JP
机构
[1] GRP HOSP PITIE SALPETRIERE,F-75634 PARIS,FRANCE
[2] HOP CLAUDE HURIEZ,LILLE,FRANCE
[3] HOP ST LOUIS,PARIS,FRANCE
[4] HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE
[5] HOP COCHIN,F-75674 PARIS,FRANCE
[6] CTR HOSP XAVIER ARMOZAN,BORDEAUX,FRANCE
[7] CTR HENRI BECQUEREL,F-76038 ROUEN,FRANCE
[8] CHU,CAEN,FRANCE
[9] HOP VAL DE GRACE,PARIS,FRANCE
[10] HOP HOTEL DIEU,PARIS,FRANCE
来源
HEMATOLOGY AND CELL THERAPY | 1996年 / 38卷 / 02期
关键词
acute myeloid leukemia; therapy;
D O I
10.1007/s00282-996-0161-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Timed sequential chemotherapy (TSC) combining mitoxantrone on days 1-3, etoposide on days 8-10 and cytarabine on days 1-3 and 8-10, was administered to 240 patients with advanced acute myelogenous leukemia (AML). Sixty one percent of patients, with a 95% confidence interval (CI) ranging from 54 to 67%, achieved complete remission (CR), including 47% (CI: 38-55%) of refractory patients and 78% (CI: 70-86%) of late first relapse patients (p < 0.0001). Thirty percent of patients did not respond to therapy and 9% died from toxicity. Median duration of neutropenia was 32 days and of thrombocytopenia 29 days. Severe non hematologic toxicity included sepsis in 45% of patients and mucositis in 27%. Post-remission therapy varied but included maintenance chemotherapy in most patients, a second course of TSC in 27, autologous stem cell transplantation in 17 and allogeneic transplantation in 20. Median survival of patients who were not transplanted was 7 months with 13% (CI: 7-19%) survival at 5 years. Median disease-free survival (DFS) was 9 months with 13% (CI: 6-20%) DFS at 5 years. Previous refractoriness was the main factor associated with poor prognosis for achieving CR, DFS and survival in a multivariate analysis. There was no difference in DFS between patients receiving the different modalities of intensive postremission therapy. These results confirm initial reports on TSC and show that some patients with first relapse off therapy can enjoy prolonged DFS using chemotherapy only.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 31 条
[1]   MITOXANTRONE, ETOPOSIDE, AND INTERMEDIATE-DOSE CYTARABINE - AN EFFECTIVE AND TOLERABLE REGIMEN FOR THE TREATMENT OF REFRACTORY ACUTE MYELOID-LEUKEMIA [J].
AMADORI, S ;
ARCESE, W ;
ISACCHI, G ;
MELONI, G ;
PETTI, MC ;
MONARCA, B ;
TESTI, AM ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1210-1214
[2]  
ARCHIMBAUD E, 1991, BLOOD, V77, P1894
[3]   TIMED SEQUENTIAL CHEMOTHERAPY FOR PREVIOUSLY TREATED PATIENTS WITH ACUTE MYELOID-LEUKEMIA - LONG-TERM FOLLOW-UP OF THE ETOPOSIDE, MITOXANTRONE, AND CYTARABINE-86 TRIAL [J].
ARCHIMBAUD, E ;
THOMAS, X ;
LEBLOND, V ;
MICHALLET, M ;
FENAUX, P ;
CORDONNIER, C ;
DREYFUS, F ;
TROUSSARD, X ;
JAUBERT, J ;
TRAVADE, P ;
TRONCY, J ;
ASSOULINE, D ;
FIERE, D .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :11-18
[4]  
ARLIN Z, 1990, LEUKEMIA, V4, P177
[5]   CRITERIA FOR THE DIAGNOSIS OF ACUTE-LEUKEMIA OF MEGAKARYOCYTE LINEAGE (M7) - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (03) :460-462
[6]   PROPOSAL FOR THE RECOGNITION OF MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-MO) [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (03) :325-329
[7]  
BENNETT JM, 1985, ANN INTERN MED, V103, P626
[8]  
BISHOP JF, 1990, BLOOD, V75, P27
[9]  
BURKE PJ, 1980, BLOOD, V55, P960
[10]  
CHAMPLIN R, 1987, BLOOD, V69, P1551